Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02753426 · ClinicalTrials.gov registry record · Phase 1
A Trial of Doxycycline in Renal Disease
A Phase 1 study of Chronic Kidney Disease and Cardiorenal Syndrome, sponsored by University of California, San Francisco.
- Completed
- Registry status
- Phase 1
- Development phase
- 11
- Enrollment target
- 1
- Study location
NCT02753426 is a Phase 1 study of Chronic Kidney Disease and Cardiorenal Syndrome that has completed, run by University of California, San Francisco. The registered enrollment target is 11 participants, below the 3,207-participant average among 101 other Chronic Kidney Disease trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02753426, a Phase 1 study of Chronic Kidney Disease and Cardiorenal Syndrome, has completed, sponsored by University of California, San Francisco.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 11 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this trial is to evaluate whether subantimicrobial-dose of doxycycline (20mgBID) will affect serum and urine biomarkers of fibrosis in patients with pre-dialysis chronic kidney disease.
Conditions Studied
Interventions
- DRUG Doxycycline
- DRUG Placebo (for Doxycycline)
Study Locations (1)
California
- Zuckerberg San Francisco General Hospital - San Francisco
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2016-04 |
| Est. Completion | 2018-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02753426
The ClinicalTrials.gov registry entry for NCT02753426 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,207-participant average among 101 other Chronic Kidney Disease trials with a reported enrollment target (100% lower). The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Chronic Kidney Disease appearing as the primary indexed condition, and to 2 interventions - of which Doxycycline is the first listed.
NCT02753426 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT02753426 about?
NCT02753426 is a clinical study titled "A Trial of Doxycycline in Renal Disease". The goal of this trial is to evaluate whether subantimicrobial-dose of doxycycline (20mgBID) will affect serum and urine biomarkers of fibrosis in patients with pre-dialysis chronic kidney disease.
What is the current status of trial NCT02753426?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 11 participants. The study started on 2016-04. Estimated completion is 2018-01.
What conditions does trial NCT02753426 study?
This clinical trial studies the following conditions: Chronic Kidney Disease, Cardiorenal Syndrome.
What interventions are being tested in trial NCT02753426?
The interventions under investigation include: Doxycycline (DRUG), Placebo (for Doxycycline) (DRUG).
Who is sponsoring clinical trial NCT02753426?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02753426 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Kidney Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Sympatholysis in Chronic Kidney Disease
RECRUITING · Phase 1
-
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of OJR520 in Healthy Volunteers and Participants With Chronic Kidney Disease
RECRUITING · Phase 1
-
A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4248 in Healthy Participants and Participants With Chronic Kidney Disease and Type 2 Diabetes and to Assess Home Measurements of Creatinine in a Non Interventional Cohort
RECRUITING · Phase 1
-
Study to Assess PK, Safety and Tolerability in Patients With DM and CKD
COMPLETED · Phase 1
-
A Study of RBT-3 in Healthy Volunteers and Volunteers With Stage 3/4 Chronic Kidney Disease
COMPLETED · Phase 1
-
Safety, Tolerability, and Pharmacokinetics of KBP-5074 Following Oral Administration in Chronic Kidney Disease
COMPLETED · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.